CR20220255A - Inhibidores de egfr - Google Patents

Inhibidores de egfr

Info

Publication number
CR20220255A
CR20220255A CR20220255A CR20220255A CR20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A CR 20220255 A CR20220255 A CR 20220255A
Authority
CR
Costa Rica
Prior art keywords
compound
egfr inhibitors
formula
medicament
pharmaceutically acceptable
Prior art date
Application number
CR20220255A
Other languages
English (en)
Inventor
Antonio Ricci
Bernd Kuhn
Yvonne Alice Nagel
Georg Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220255A publication Critical patent/CR20220255A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud proporciona un compuesto que tiene la Fórmula general (I) o una sal farmacéuticamente aceptable de este, composiciones que incluyen el compuesto y métodos de uso del compuesto. El compuesto de Fórmula (I) se puede usar como un medicamento.
CR20220255A 2019-12-20 2020-12-18 Inhibidores de egfr CR20220255A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19218403 2019-12-20
PCT/EP2020/086914 WO2021123084A1 (en) 2019-12-20 2020-12-18 Egfr inhibitors

Publications (1)

Publication Number Publication Date
CR20220255A true CR20220255A (es) 2022-07-11

Family

ID=69411052

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220255A CR20220255A (es) 2019-12-20 2020-12-18 Inhibidores de egfr

Country Status (18)

Country Link
US (1) US20230034696A1 (es)
EP (1) EP4076664B1 (es)
JP (1) JP7737991B2 (es)
KR (1) KR20220118426A (es)
CN (1) CN114867531B (es)
AR (1) AR120799A1 (es)
AU (1) AU2020405326A1 (es)
BR (1) BR112022011690A2 (es)
CA (1) CA3160534A1 (es)
CL (1) CL2022001353A1 (es)
CO (1) CO2022006965A2 (es)
CR (1) CR20220255A (es)
IL (1) IL292104A (es)
MX (1) MX2022007634A (es)
PE (1) PE20221768A1 (es)
PH (1) PH12022551241A1 (es)
TW (1) TW202136263A (es)
WO (1) WO2021123084A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288522B2 (en) 2019-06-21 2025-02-01 Hoffmann La Roche EGFR inhibitor for cancer treatment
AU2020383423A1 (en) 2019-11-11 2022-06-23 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4255907A1 (en) 2020-12-01 2023-10-11 F. Hoffmann-La Roche AG New indazole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
JP6845165B2 (ja) * 2015-06-30 2021-03-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤およびその使用方法
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GB201519644D0 (en) * 2015-11-06 2015-12-23 Univ Southampton Therapy and pharmaceutical composition
US11672801B2 (en) * 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
TW201945357A (zh) * 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2019183523A1 (en) * 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
PE20211388A1 (es) * 2018-06-29 2021-07-27 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
CA3160534A1 (en) 2021-06-24
PH12022551241A1 (en) 2023-10-09
US20230034696A1 (en) 2023-02-02
CL2022001353A1 (es) 2023-02-17
CN114867531A (zh) 2022-08-05
CO2022006965A2 (es) 2022-06-10
AU2020405326A1 (en) 2022-05-12
MX2022007634A (es) 2022-07-19
CN114867531B (zh) 2024-03-22
JP7737991B2 (ja) 2025-09-11
EP4076664A1 (en) 2022-10-26
TW202136263A (zh) 2021-10-01
IL292104A (en) 2022-06-01
EP4076664C0 (en) 2023-08-30
BR112022011690A2 (pt) 2022-09-06
PE20221768A1 (es) 2022-11-11
AR120799A1 (es) 2022-03-16
KR20220118426A (ko) 2022-08-25
JP2023506809A (ja) 2023-02-20
EP4076664B1 (en) 2023-08-30
WO2021123084A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
PH12022551503A1 (en) Kras mutant protein inhibitors
PH12022550098A1 (en) Parp1 inhibitors
PH12022551241A1 (en) Egfr inhibitors
GEAP202215540A (en) Pcsk9 antagonist compounds
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MY209340A (en) Egfr inhibitor for the treatment of cancer
EA202193015A1 (ru) Ингибиторы cdk
NZ766978A (en) Atr inhibitor and application thereof
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MX2021013981A (es) Inhibidores de la cinasa aurora y usos de los mismos.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
TN2017000374A1 (en) TGF-β INHIBITORS
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PH12019501639B1 (en) Jak1 selective inhibitors
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MY189557A (en) Pyridone compound as c-met inhibitor
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
MY209603A (en) Hydroxypyridoxazepines as nrf2 activators
PH12022550130A1 (en) Enzyme inhibitors
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12021552513A1 (en) Pyrrole compounds
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)